Quality Care in U.S. Hospitals: Good, Bad, or Improving?

Quality Care in U.S. Hospitals: Good, Bad, or Improving? Quality of care in hospitals and other health centers across the United States has shown improvements over the past eight years, a national health care accrediting organization revealed.

According to a report from Businessweek, The Joint Commission found that there is a big improvement on US hospitals in caring for patients with heart attack, pneumonia, surgery and children’s asthma.

Continue reading “Quality Care in U.S. Hospitals: Good, Bad, or Improving?”









Krystexxa Anti-Gout Drug Approved by FDA

Krystexxa Anti-Gout Drug Approved by FDA. The U.S Food and Drug Administration has approved a drug to cure gout among adults who cannot tolerate or respond to existing treatments.

The US FDA approved Krystexxa to treat the painful condition which is characterized by swelling, redness, heat, pain and stiffness in the joints. Kyystexxa lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine.

“Since one out of every four patients in the clinical trials experienced a severe allergic reaction when receiving an infusion of Krystexxa, health care providers should dispense a corticosteroid and an antihistamine to their patients beforehand to minimize the risk of such a reaction. Other reactions during the clinical trials included gout flare, nausea, injection site bruising, irritation of the nasal passages, constipation, chest pain and vomiting”, the FDA news release says.

Continue reading “Krystexxa Anti-Gout Drug Approved by FDA”









Drooling Treatment for Kids: Cuvposa Gains FDA Approval

Drooling Treatment for Kids: Cuvposa Gains FDA Approval. Are your kids suffering from chronic drooling and you don’t know how to treat their condition?

They might be able to gain relief from the Cuvposa (glycopyrrolate) Oral Solution which was approved today by the U.S. Food and Drug Administration (FDA) to treat “chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years”.

Concerned about Cuvposa’s side effects? According to the FDA, the common adverse reactions reported with glycopyrrolate are dry mouth, constipation, flushing, and urinary retention.

Continue reading “Drooling Treatment for Kids: Cuvposa Gains FDA Approval”